+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Agenus Inc - logo

Agenus is an immuno-oncology company that focuses on the discovery and development of treatments that engage the body's immune system for patients suffering with cancer. The company offers Retrocyte Display, an antibody discovery platform that screens and generates therapeutic antibody drug candidates. It is also developing Prophage, a heat shock protein-based autologous vaccine. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

Glioblastoma Multiforme (GBM) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Glioblastoma Multiforme (GBM) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • December 2022
  • 1036 Pages
  • Global
From
Endometrial Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Endometrial Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • October 2022
  • 532 Pages
  • Global
From
Prostate Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Prostate Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • November 2022
  • 1663 Pages
  • Global
From
Precision Immuno-Oncology Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F - Product Thumbnail Image

Precision Immuno-Oncology Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F

  • Report
  • November 2023
  • 178 Pages
  • Global
From
NK Cell therapies - Pipeline Insight, 2024 - Product Thumbnail Image

NK Cell therapies - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 120 Pages
  • Global
From
Melanoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Melanoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • November 2022
  • 1699 Pages
  • Global
From
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • December 2022
  • 1560 Pages
  • Global
From
PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Global Market Report 2024 - Product Thumbnail Image

PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Global Market Report 2024

  • Report
  • January 2024
  • 200 Pages
  • Global
From
Soft Tissue Sarcoma - Pipeline Insight, 2024 - Product Thumbnail Image

Soft Tissue Sarcoma - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 250 Pages
  • Global
From
TIGIT inhibitors - Pipeline Insight, 2024 - Product Thumbnail Image

TIGIT inhibitors - Pipeline Insight, 2024

  • Drug Pipelines
  • January 2024
  • 60 Pages
  • Global
From
4-1BB receptor Agonist - Pipeline Insight, 2024 - Product Thumbnail Image

4-1BB receptor Agonist - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 100 Pages
  • Global
From
Cervical Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Cervical Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • October 2022
  • 700 Pages
  • Global
From
CTLA-4 inhibitors- Competitive landscape, 2023 - Product Thumbnail Image

CTLA-4 inhibitors- Competitive landscape, 2023

  • Report
  • May 2023
  • 220 Pages
  • Global
From
Checkpoint Inhibitors - Competitive landscape, 2023 - Product Thumbnail Image

Checkpoint Inhibitors - Competitive landscape, 2023

  • Report
  • April 2023
  • 350 Pages
  • Global
From
CD137 Agonist Antibody - Pipeline Insight, 2024 - Product Thumbnail Image

CD137 Agonist Antibody - Pipeline Insight, 2024

  • Drug Pipelines
  • January 2024
  • 60 Pages
  • Global
From
Pancreatic Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Pancreatic Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • July 2022
  • 3237 Pages
  • Global
From
OX-40 Agonist - Pipeline Insight, 2024 - Product Thumbnail Image

OX-40 Agonist - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Checkpoint Inhibitor Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application - Product Thumbnail Image

Checkpoint Inhibitor Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application

  • Report
  • January 2024
  • 94 Pages
  • Global
From
Cervical Cancer Drugs Global Market Report 2024 - Product Thumbnail Image

Cervical Cancer Drugs Global Market Report 2024

  • Report
  • February 2024
  • 175 Pages
  • Global
From
Oncolytic Virus - Competitive Landscape, 2022 - Product Thumbnail Image

Oncolytic Virus - Competitive Landscape, 2022

  • Report
  • October 2022
  • 300 Pages
  • Global
From
Loading Indicator